Form 8-K - Current report:
SEC Accession No. 0001558370-25-011227
Filing Date
2025-08-12
Accepted
2025-08-12 16:16:23
Documents
16
Period of Report
2025-08-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K armp-20250811x8k.htm   iXBRL 8-K 47520
2 EX-10.1 armp-20250811xex10d1.htm EX-10.1 537391
3 EX-99.1 armp-20250811xex99d1.htm EX-99.1 207970
4 GRAPHIC armp-20250811xex99d1001.jpg GRAPHIC 3047
  Complete submission text file 0001558370-25-011227.txt   1031284

Data Files

Seq Description Document Type Size
5 EX-101.SCH armp-20250811.xsd EX-101.SCH 4131
6 EX-101.DEF armp-20250811_def.xml EX-101.DEF 2858
7 EX-101.LAB armp-20250811_lab.xml EX-101.LAB 16593
8 EX-101.PRE armp-20250811_pre.xml EX-101.PRE 10917
18 EXTRACTED XBRL INSTANCE DOCUMENT armp-20250811x8k_htm.xml XML 4656
Mailing Address 5005 MCCONNELL AVE LOS ANGELES CA 90066
Business Address 5005 MCCONNELL AVE LOS ANGELES CA 90066 310-665-2928
Armata Pharmaceuticals, Inc. (Filer) CIK: 0000921114 (see all company filings)

EIN.: 911549568 | State of Incorp.: WA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37544 | Film No.: 251206932
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)